2701 EASTLAKE AVE EAST, SEATTLE, WA
Financial Results, Press Release
Nautilus Biotechnology Elects Class II Directors at Annual Meeting
Annual Report to Security Holders
Reports First Quarter 2026 Financial Results
Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Other Events
Reports Third Quarter 2025 Financial Results
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement